Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Amrubicin

Introduction

Overview

Overview

Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.[1] It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed.[2]

Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.[3] [4]

It has also been studied for the treatment of bladder carcinoma[5] and gastric cancer.[6]

References

References

  1. ↑ Ueoka H, Ohnoshi T, Kimura I (November 1992). “[New anthracycline analogues in the treatment of lung cancer]”. Gan To Kagaku Ryoho (in Japanese). 19 (13): 2146–9. PMID 1332624.
  2. ↑ Sumitomo Pharmaceuticals Co., Ltd. (2003). “CALSED for Injection (English)” (PDF). Retrieved 2008-08-17.
  3. ↑ Celgene Corporation (2008). “Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer”. Retrieved 2009-07-10.
  4. ↑ Medical News Today (2007). “Pharmion’s Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer”. Retrieved 2009-07-10.
  5. ↑ Ohmori H, Tsushima T, Kobashi K (April 1996). “[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]”. Gan To Kagaku Ryoho (in Japanese). 23 (5): 601–6. PMID 8678519.
  6. ↑ Tsushima K, Sakata Y, Munakata A; et al. (June 1991). “[A phase II study of SM-5887 for advanced gastric cancer]”. Gan To Kagaku Ryoho (in Japanese). 18 (7): 1151–4. PMID 1647150.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]